BACKGROUND: Obestatin is a novel hormone that is encoded by the Ghrelin gene and produced in the gut. Ghrelin is profoundly orexogenic and adipogenic, increasing food intake and body weight. This new ghrelin-associated peptide behaves as a physiological opponent of ghrelin in rodent animals, but its pathophysiological role in humans remains unknown OBJECTIVE: In this study we investigate whether plasma obestatin level is different in patients with impaired glucose regulation (IGR) and type 2 diabetes mellitus (T2DM). PATIENTS AND MEASUREMENTS: Forty-seven patients with T2DMu, 30 subjects with IGR, and 38 sex- and age-matched normal controls participated in the study. Plasma obestatin levels were measured with a radioimmunoassay. The relationship between plasma obestatin levels and anthropometric and metabolic parameters was also analysed. RESULTS: Plasma obestatin levels were lower in patients with T2DM and IGR than in controls (37.5 +/- 9.2 ng/l and 39.2 +/- 9.7 ng/l vs. 43.8 +/- 8.0 ng/l, P = 0.002 and P = 0.039, respectively). Decreasing concentrations of obestatin were independently and significantly associated with IGR and T2DM. Multiple logistic regression analysis revealed obestatin to be independently associated with IGR and T2DM. In a multiple linear regression analysis, only waist-to-hip ratio and homeostasis model assessment of insulin resistance (HOMA-IR) were independently associated with plasma obestatin level. CONCLUSION: Our results suggest that obestatin may play a role in appetite regulation in patients with IGR and T2DM.
BACKGROUND:Obestatin is a novel hormone that is encoded by the Ghrelin gene and produced in the gut. Ghrelin is profoundly orexogenic and adipogenic, increasing food intake and body weight. This new ghrelin-associated peptide behaves as a physiological opponent of ghrelin in rodent animals, but its pathophysiological role in humans remains unknown OBJECTIVE: In this study we investigate whether plasma obestatin level is different in patients with impaired glucose regulation (IGR) and type 2 diabetes mellitus (T2DM). PATIENTS AND MEASUREMENTS: Forty-seven patients with T2DMu, 30 subjects with IGR, and 38 sex- and age-matched normal controls participated in the study. Plasma obestatin levels were measured with a radioimmunoassay. The relationship between plasma obestatin levels and anthropometric and metabolic parameters was also analysed. RESULTS: Plasma obestatin levels were lower in patients with T2DM and IGR than in controls (37.5 +/- 9.2 ng/l and 39.2 +/- 9.7 ng/l vs. 43.8 +/- 8.0 ng/l, P = 0.002 and P = 0.039, respectively). Decreasing concentrations of obestatin were independently and significantly associated with IGR and T2DM. Multiple logistic regression analysis revealed obestatin to be independently associated with IGR and T2DM. In a multiple linear regression analysis, only waist-to-hip ratio and homeostasis model assessment of insulin resistance (HOMA-IR) were independently associated with plasma obestatin level. CONCLUSION: Our results suggest that obestatin may play a role in appetite regulation in patients with IGR and T2DM.
Authors: D H St-Pierre; F Settanni; I Olivetti; E Gramaglia; M Tomelini; R Granata; F Prodam; A Benso; E Ghigo; F Broglio Journal: J Endocrinol Invest Date: 2010-05-05 Impact factor: 4.256
Authors: Andrew J Agnew; Emma Robinson; Carmel M McVicar; Adam P Harvey; Imran H A Ali; Jennifer E Lindsay; Denise M McDonald; Brian D Green; David J Grieve Journal: Br J Pharmacol Date: 2012-05 Impact factor: 8.739